Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus by Masato Odawara et al.
ORIGINAL RESEARCH
Efficacy and Safety of Vildagliptin as Add-on
to Metformin in Japanese Patients with Type 2
Diabetes Mellitus
Masato Odawara • Izumi Hamada • Manabu Suzuki
To view enhanced content go to www.diabetestherapy-open.com
Received: January 23, 2014 / Published online: March 7, 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: The objective of this study was to
evaluate the efficacy and safety of vildagliptin, a
potent dipeptidyl peptidase-4 inhibitor, as an
add-on to metformin in Japanese patients with
type 2 diabetes mellitus (T2DM).
Methods: This multicenter, 12-week,
randomized, double-blind, placebo-controlled,
parallel-arm study compared vildagliptin 50 mg
bid with placebo in T2DM patients who were
inadequately controlled [glycosylated
hemoglobin (HbA1c) 7.0–10.0%] on a stable
daily dose of metformin monotherapy (250 mg
bid or 500 mg bid).
Results: A total of 139 patients were
randomized to receive either vildagliptin
(n = 69) or placebo (n = 70). Patient
demographics were comparable between the
groups at baseline. After 12 weeks of
treatment, adjusted mean change in HbA1c
was -1.1% in the vildagliptin group (baseline
8.0%) and -0.1% in the placebo group (baseline
8.0%), with a between-treatment difference of
-1.0% (P\0.001). Vildagliptin showed a
similar reduction in HbA1c of -1.1% for both
the subpopulations of patients receiving
metformin 250 mg bid or 500 mg bid
(P\0.001 vs. baseline). Significantly more
patients in the vildagliptin group achieved an
HbA1c target of B6.5% (30.9%) and \7.0%
(64.1%) compared with the placebo group
(P\0.001). The between-treatment difference
in adjusted mean change in fasting plasma
glucose was -1.6 mmol/L (P\0.001) in favor
of vildagliptin. Patients in the vildagliptin and
placebo groups reported comparable incidences
of adverse events (44.1% vs. 41.4%). No deaths
or hypoglycemic events were reported in the
study.
Conclusions: Vildagliptin 50 mg bid added to
metformin improved glycemic control without
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any tolerability issues and hypoglycemia in
Japanese patients with T2DM inadequately
controlled on metformin monotherapy.
Keywords: Antidiabetic drug; Dipeptidyl
peptidase-4 inhibitor; Glycemic control;
Metformin; Randomized trial; Type 2 diabetes
mellitus; Vildagliptin
INTRODUCTION
In Japan, the estimated number of individuals with
type 2 diabetes mellitus (T2DM) is approximately
7.1 million, which is the ninth largest prevalence
in the world [1]. In recent years, the prevalence of
T2DM in Japan has increased due to lifestyle
changes, genetic predisposition, and an aging
population [2, 3]. Most of the Japanese T2DM
patients are non-obese with an average body mass
index (BMI) of 23–25 kg/m2, impaired insulin
secretion plays a key role in the development of
T2DM in these patients [4].
Despite major advances in the management
of T2DM and availability of a range of
antidiabetic agents, evidence suggests that up
to *60% of patients in Japan [5] fail to achieve
the recommended target of glycosylated
hemoglobin (HbA1c) levels \7.0% [6].
Metformin is one of the commonly used oral
antidiabetic agents (OADs) in Japan. Metformin
improves blood glucose levels primarily by
inhibiting hepatic glucose production and also
improving insulin sensitivity in the liver and
skeletal muscles [7]. However, due to the
progressive nature of T2DM, long-term glycemic
control is difficult to achieve with a single agent,
thus often requiring addition of further agents.
Addition of a dipeptidyl peptidase-4 (DPP-4)
enzyme inhibitor with metformin is beneficial
due to their complementary mechanisms of
action [8].
Vildagliptin, a potent and selective DPP-4
inhibitor, increases the active levels of incretin
hormones, glucagon-like peptide (GLP)-1 and
glucose-dependent insulinotropic polypeptide
(GIP), thereby improving pancreatic a- and b-
cell sensitivity to glucose [9]. In large-scale
clinical trials, vildagliptin improved glycemic
control when given as monotherapy [10] or in
combination with metformin [11], sulfonylurea
[12], thiazolidinedione [13] or insulin [14], with
low risk of hypoglycemia and weight gain.
Vildagliptin 50 mg bid showed notable
improvement in blood glucose levels and better
tolerability compared with placebo [15] or
voglibose [16] in Japanese patients with T2DM
inadequately controlled on diet and exercise.
Combination therapy of vildagliptin with low-
dose (500 mg bid) and high-dose (1,000 mg bid)
metformin showed improved glycemic control
compared with individual monotherapies in a
large global study [17]. The high dose of
metformin ([750 mg/day) was approved in
Japan in 2010. However, there are limited
clinical data on the use of DPP-4 inhibitors in
combination with metformin ([750 mg/day) in
Japanese patients with T2DM. The aim of the
present study was to evaluate the efficacy and
safety of vildagliptin as add-on therapy in
Japanese patients with T2DM inadequately
controlled with metformin 500 or 1,000 mg/
day. The study was conducted to support
registration of the fixed-dose combination of




This was a 12-week, multicenter, randomized,
double-blind, parallel-group, placebo-controlled
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study conducted across 20 centers in Japan in
patients with T2DM inadequately controlled on
metformin and diet/exercise. Following a
screening period (visit 1), eligible patients who
were on a stable daily dose of metformin (250 mg
bid or 500 mg bid) for at least 10 weeks proceeded
directly to randomization (baseline, visit 2) to
receive either vildagliptin 50 mg bid or placebo
as add-on to metformin in a 1:1 ratio. Patients
taking OADs other than metformin were
switched to either metformin 250 mg bid or
500 mg bid at the investigator’s discretion and
were randomized after completing a 12-week
run-in period (Fig. 1). This was followed by three
scheduled visits from baseline (weeks 4, 8, and
12) during which efficacy and tolerability were
assessed. Randomization was stratified to adjust
for metformin dose in 1:1 ratio in both the
treatment groups. The dose of metformin
remained unchanged throughout the study and
no rescue medication (additional OADs or
insulin) was allowed. Patients with
unsatisfactory therapeutic effect [fasting plasma
glucose (FPG) C15.0 mmol/L] were to be
discontinued from the study.
Study Population
The study enrolled men and women with
T2DM, aged C20 to \75 years, BMI C20 to
B35 kg/m2, baseline HbA1c values C7.0% to
B10.0%, who were inadequately controlled on
diet, exercise and metformin monotherapy. The
patients were required to be on a stable daily
dose of metformin 250 mg bid or 500 mg bid for
at least 10 weeks prior to randomization.
The key exclusion criteria included history of
type 1 diabetes, diabetes due to pancreatic
injury or secondary forms, acute metabolic
complications such as ketoacidosis or lactic
acidosis, liver diseases such as cirrhosis or
hepatitis, impaired renal function, congestive
heart failure (New York Heart Association Class
III or IV), myocardial infarction, stroke or
transient ischemic attacks in the past
6 months. Patients with any of the following
laboratory abnormalities at baseline were
excluded: FPG C15 mmol/L; alanine
transaminase, aspartate transaminase, or total
bilirubin [2 times the upper limit of normal;
and fasting triglycerides [5.7 mmol/L.
Fig. 1 Study design
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Study Endpoints and Assessments
The primary efficacy endpoint was the change
in HbA1c from baseline to week 12 or the study
endpoint. The key secondary efficacy endpoint
was change in HbA1c from baseline to study
endpoint within subpopulations of patients
treated with vildagliptin and metformin
(250 mg bid or 500 mg bid). Other secondary
efficacy endpoints included percentage of
patients (responder rate) achieving predefined
HbA1c targets (B6.5%,\7.0%, and reductions of
C0.5% and C1.0%) and change in FPG levels
after 12 weeks of treatment. Changes in HbA1c
(reported in National Glycohemoglobin
Standardization Program units) and FPG were
assessed at each scheduled visit (weeks 0, 4, 8,
and 12).
Adverse events (AEs) and serious AEs (SAEs)
were recorded at each visit, and were assessed
for severity, duration, and suspected
relationship to the study drug. Standard
hematology, biochemistry, liver function tests,
urinalysis, vital signs, and body weight were
measured at the screening visit and at weeks 0,
4, 8, and 12. Electrocardiograms were recorded
at screening and at the last study visit (week 12).
Fasting lipid profile was assessed at baseline and
at the last study visit. All the patients were
provided with a calibrated home glucose
monitor and were instructed regarding its use.
The patients were educated regarding
hypoglycemic symptoms, possible triggers and
were asked to record hypoglycemic event in a
study diary. Hypoglycemia was defined as
symptoms suggestive of hypoglycemia that
was further confirmed by a self-monitored
blood glucose measurement of \3.1 mmol/L.
The event was considered grade 1 if the patient
was able to initiate self-treatment, and grade 2 if
the patient required assistance of another
person or hospitalization. All the laboratory
assessments were performed at a central
laboratory (Mitsubishi Chemical Medience
Corporation, Japan).
Statistical Analysis
A total of 136 patients (68 patients per group)
were to be randomized (1:1) to achieve a target
sample size of 128 patients (64 per group),
assuming a dropout rate of 5%. This sample size
would ensure at least 92% power to detect a
clinically relevant between-group difference of
0.6% absolute units in HbA1c change from
baseline, assuming a one-sided significance
level of 0.025, to demonstrate the superiority
of vildagliptin 50 mg bid over placebo as add-on
to metformin in reducing HbA1c after 12 weeks
of treatment. Moreover, randomization was
stratified by metformin dose to ensure that
patients on metformin 250 mg bid and 500 mg
bid each constituted *50% of the randomized
population. The planned sample size of 136
patients (34 patients in each metformin
subpopulation in the vildagliptin group)
would provide at least 90% power to detect a
statistically significant reduction in HbA1c of
0.6% from baseline in each metformin
subgroup (250 mg bid or 500 mg bid),
assuming a one-sided significance level of
0.025.
The primary and secondary efficacy analyses
were based on the full analysis set, which
included all randomized patients who received
at least one dose of the study drug and had at
least one post-randomization efficacy parameter
assessment. Changes in HbA1c and FPG from
baseline to study endpoint were analyzed using
the analysis of covariance model (ANCOVA),
with treatment groups and metformin dose as
classification variables and baseline HbA1c as
covariate. The study endpoint is the final
available post-randomization assessment value
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at any visit (scheduled or unscheduled) up to
final visit (week 12). The between-treatment
difference in HbA1c and FPG was also analyzed
using ANCOVA. Change in HbA1c from baseline
to study endpoint within the metformin
subpopulations was analyzed using a paired
t test. Missing data because of early
discontinuation were handled using the last
observation carried forward method. The
impact of various baseline characteristics (age,
gender, BMI, HbA1c, and FPG) on absolute
change in HbA1c from baseline to endpoint
was analyzed using descriptive statistics. The
proportion of responders (HbA1c B6.5% at
endpoint, HbA1c \7% at endpoint, and
reductions in HbA1c C0.5% and C1%) in each
treatment group was computed and compared
using the Chi-square test. The data analysis for
this study was carried out using SAS software
(version 9.2, SAS Institute Inc., Cary, NC, USA).
The safety set consisted of all patients who
received at least one dose of the study drug.
Safety data were summarized descriptively by
treatment. The incidences of treatment-
emergent AEs were summarized by system
organ class (SOC), preferred term (PT),
severity, and relationship to the study drug.
AEs were coded by primary SOC and PT
according to Medical Dictionary for Drug
Regulatory Activities (MedDRA version 15.1).
Ethics and Good Clinical Practice
The study protocol was reviewed and approved
by the Independent Ethics Committee/
Institutional Review Board at each center. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national), the Helsinki
Declaration of 1975, as revised in 2000 and
2008 and Good Clinical Practice guidelines.
Informed consent was obtained from all
patients for being included in the study. The
study is registered with ClinicalTrials.gov,
identifier: NCT01497522.
RESULTS
Patient Disposition and Baseline
Characteristics
Of the 139 randomized patients (vildagliptin,
n = 69; placebo, n = 70), 133 patients (95.7%)
completed the study (Fig. 2). The primary
reasons for discontinuation in the study were
AEs (3 patients) and protocol deviations (2
patients) (Fig. 2). Patient demographics and
baseline characteristics were comparable
between the treatment groups (Table 1).
Overall mean age, BMI, baseline HbA1c,
baseline FPG, and duration of T2DM were
58.1 years, 25.6 kg/m2, 8.0%, 9.2 mmol/L, and
7.1 years, respectively. The patients were
predominantly men (66.2%), and more
patients were aged C65 years in the
Fig. 2 Patient disposition
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vildagliptin group (31.9%) than in the placebo
group (22.9%).
Efficacy
The mean change in HbA1c during the
12 weeks of treatment was consistently lower
with vildagliptin than with placebo (Fig. 3a).
The overall adjusted mean change (AMD) ± SE
in HbA1c was -1.1 ± 0.06% in the vildagliptin
group (baseline 8.0%) and -0.1 ± 0.06% in
the placebo group (baseline 8.0%), with a
statistically significant between-treatment
difference of -1.0 ± 0.09% (P\0.001) in
favor of vildagliptin (Fig. 3b). Vildagliptin
also showed statistically significant reductions
from baseline in HbA1c for subpopulations of
patients receiving metformin 250 mg bid and
500 mg bid (Table 2). Significantly more
patients with vildagliptin achieved HbA1c
targets of B6.5% (30.9%) and \7.0% (64.1%)
compared with placebo (P\0.001). A higher








Age, years 58.7 (9.81) 57.5 (9.15) 58.1 (9.47)
C65 years, n (%) 22 (31.9) 16 (22.9) 38 (27.3)
Men, n (%) 44 (63.8) 48 (68.6) 92 (66.2)
Body weight, kg 67.9 (12.70) 70.0 (13.02) 68.9 (12.85)
BMI, kg/m2 25.3 (3.56) 25.9 (4.01) 25.6 (3.79)
HbA1c, % 8.0 (0.83) 8.0 (0.96) 8.0 (0.90)
B8%, n (%) 40 (58.0) 40 (57.1) 80 (57.6)
[8 to B9%, n (%) 17 (24.6) 14 (20.0) 31 (22.3)
[9%, n (%) 12 (17.4) 16 (22.9) 28 (20.1)
FPG, mmol/L 9.1 (1.80) 9.3 (2.40) 9.2 (2.12)
C8.9 mmol/L, n (%) 28 (40.6) 36 (51.4) 64 (46.0)
Duration of T2DM, years 7.2 (6.18) 7.0 (5.92) 7.1 (6.03)
Metformin total daily dose, mg 753.6 (251.81) 750.0 (251.81) 751.8 (250.90)
Metformin B500 mg/day, n (%) 34 (49.3) 35 (50.0) 69 (49.6)
Metformin[500 mg/day, n (%) 35 (50.7) 35 (50.0) 70 (50.4)
eGFR (MDRD), mL/min/1.73 m2, n (%)
Normal,[80 66 (95.7) 64 (91.4) 130 (93.5)
Mild, C50 to B80 3 (4.3) 6 (8.6) 9 (6.5)
Moderate, C30 to\50 0 (0.0) 0 (0.0) 0 (0.0)
Values are expressed as mean (standard deviation) unless speciﬁed otherwise
BMI body mass index, eGFR estimated glomerular ﬁltration rate, FPG fasting plasma glucose, HbA1c glycosylated
hemoglobin, MDRD modiﬁcation of diet in renal disease, OADs oral antidiabetic drugs, T2DM type 2 diabetes mellitus
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proportion of patients in the vildagliptin
group achieved HbA1c reductions of C1%
and C0.5% than in the placebo group
(P\0.001) (Table 3).
The mean changes in HbA1c from baseline to
endpoint in the subgroups of patients by age,
gender, baseline BMI, baseline HbA1c and
baseline FPG are presented in Table 4. The
mean changes in HbA1c were greater for
vildagliptin compared with placebo across all
the subgroups. Mean reductions in HbA1c in the
vildagliptin group were higher in the subgroups
of patients with higher baseline HbA1c (HbA1c
[8% to B9% or [9%) or FPG (C8.9 mmol/L)
and in those with lower baseline BMI (\25 kg/m2).
Vildagliptin showed sustained reduction in
FPG over placebo during the 12 weeks of
treatment (Fig. 4a). The AMD ± SE in FPG from
baseline to endpoint was greater in patients
receiving vildagliptin (-1.7 ± 0.16 mmol/L)
compared with those receiving placebo
(-0.1 ± 0.16 mmol/L), with a between-treatment
difference of -1.6 ± 0.22 mmol/L (P\0.001)
(Fig. 4b).
Safety
The overall proportion of patients experiencing
AEs was comparable between the vildagliptin
(44.1%) and placebo (41.4%) groups. The most
commonly reported AE by primary SOC was
‘‘infections and infestations’’ (13.2% for
vildagliptin and 14.3% for placebo). The most
frequently reported AE (C2% in any group) by
PT was ‘‘nasopharyngitis’’ (7.4% for vildagliptin
and 5.7% for placebo) (Table 5). While
incidence of AEs was low across PTs in both
the treatment groups, ‘‘amylase increased’’ was
reported in more patients with vildagliptin (4
patients; 5.9%) than with placebo (1 patient;
1.4%) and anemia was more frequent with
placebo (3 patients; 4.3%) than with
vildagliptin (0 patient). All the events of
increased amylase levels were classified as mild
and clinically asymptomatic. All the reported
AEs were mild or moderate in severity. The
incidence of AEs suspected to be related to the
study drug was slightly higher in the
vildagliptin group than in the placebo group
(16.2% vs. 10.0%). One patient in the
vildagliptin group and two patients in the
placebo group discontinued the study. No
SAEs were reported in the vildagliptin group,
whereas one SAE of myocardial infarction was
reported in the placebo group. There were no
deaths during the study. No hypoglycemic
events were reported in the study. There was
Fig. 3 a Mean glycosylated hemoglobin (HbA1c) by
treatment and visit (full analysis set). b Adjusted mean
change in HbA1c from baseline to endpoint (full analysis
set). BL baseline, EP endpoint, SE standard error.
*P\0.001
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no change in body weight from baseline to
endpoint for both treatment groups (?0.3 kg for
vildagliptin and -0.2 kg for placebo). There
were no clinically relevant changes or trends
in the hematological, biochemical (including
lipid parameters), hepatic enzyme, urinalysis
parameters, and vital signs in either treatment
group.
DISCUSSION
This 12-week, randomized, double-blind study
evaluated the efficacy and safety of vildagliptin
50 mg bid in Japanese patients with T2DM
inadequately controlled on metformin
monotherapy. Vildagliptin produced a
statistically significant and clinically
meaningful change in HbA1c compared with
placebo (-1.1% vs. -0.1%; P\0.001) as add-on
to metformin (250 mg bid or 500 mg bid) after
12 weeks of treatment in Japanese patients with
T2DM. Despite the lower baseline mean HbA1c
and daily dose of metformin in this study, the
between-treatment difference (-1.0%) seen was
consistent with the findings previously reported
in a predominantly Caucasian population,
where vildagliptin-treated patients showed a
decrease in HbA1c of 1.1% vs. placebo over
24 weeks of treatment [11]. Moreover, the
reduction in HbA1c levels reported with
vildagliptin therapy was consistent with other
DPP-4 inhibitors with different study designs in
Japanese population [18–20]. These findings
indicate that vildagliptin is effective in
Japanese patients with T2DM when added to
metformin monotherapy.
Further, vildagliptin showed statistically
significant and clinically meaningful reduction
Table 3 HbA1c responder rates (full analysis set)
Responder criteria Vildagliptin1 metformin n5 68 Placebo 1 metformin n5 70
HbA1c B6.5%, n/N
a (%) 21/68 (30.9)* 2/70 (2.9)
HbA1c\7.0%, n/N
b (%) 41/64 (64.1)* 9/59 (15.3)
Reduction of HbA1c C1%, n/N
c (%) 39/68 (57.4)* 3/70 (4.3)
Reduction of HbA1c C0.5%, n/N
c (%) 59/68 (86.8)* 13/70 (18.6)
HbA1c glycosylated hemoglobin
* P\0.001
a Denominator includes patients with a baseline of HbA1c[6.5% and endpoint HbA1c measurement
b Denominator includes patients with a baseline of HbA1c C7% and endpoint HbA1c measurement
c Denominator includes patients with both baseline and endpoint HbA1c measurements
Table 2 Change in HbA1c (%) in subpopulations of patients taking metformin 250 mg bid or 500 mg bid (full analysis set)
Treatment n Baseline mean (SE) Mean change (SE) 95% CI (P value)
Vildagliptin ? metformin 250 mg bid 34 7.9 (0.13) -1.1 (0.09) -1.24, -0.88 (P\0.001)
Vildagliptin ? metformin 500 mg bid 34 8.1 (0.15) -1.1 (0.09) -1.24, -0.88 (P\0.001)
CI conﬁdence interval, HbA1c glycosylated hemoglobin, SE standard error
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in HbA1c after 12 weeks of treatment in the
subpopulation of patients receiving metformin
250 mg bid or 500 mg bid. Treatment with
vildagliptin produced greater reduction in
HbA1c compared with placebo regardless of
age, gender, baseline BMI, HbA1c and FPG.
Vildagliptin was efficacious irrespective of the
baseline HbA1c. Greater reduction was seen in
patients with higher baseline, which is
consistent with the results observed in a
predominantly Caucasian population [11].
Approximately one-third of patients treated
with vildagliptin (30.9%) achieved the
predefined HbA1c target of B6.5%.
Furthermore, almost two-thirds of patients
(64.1%) reached the HbA1c target of \7.0%, a
goal recommended by the Japanese Diabetes
Society [6]. The responder rate (\7.0%) was
higher than that reported in a predominantly
Caucasian population (55.4%) [11]. Over half of
the population (57.4%) achieved an HbA1c
reduction of C1.0%, and 86.8% of patients
reported a reduction of C0.5% in the
vildagliptin group.
Vildagliptin showed statistically significant
reduction in FPG levels vs. placebo (P\0.001) as
add-on to metformin monotherapy after
12 weeks of treatment. The decrease in FPG
could be attributed to increased active levels of
GLP-1 upon twice-daily administration of
vildagliptin 50 mg, which enhances insulin
secretion and suppresses glucagon levels
Table 4 Mean changes in HbA1c (%) from baseline to endpoint by subgroups (full analysis set)
Subgroups Vildagliptin1 metformin n5 68 Placebo1 metformin n5 70
n BL mean Change (SE) N BL mean Change (SE)
Age (years)
\65 47 7.9 -1.1 (0.08) 54 8.0 -0.1 (0.08)
C65 21 8.3 -1.1 (0.15) 16 7.9 -0.2 (0.08)
Gender
Male 44 7.9 -1.0 (0.10) 48 8.1 -0.2 (0.07)
Female 24 8.2 -1.2 (0.09) 22 7.9 -0.1 (0.13)
BMI (kg/m2)
\25 32 8.0 -1.2 (0.11) 35 7.8 -0.2 (0.08)
C25 36 8.0 -0.9 (0.08) 35 8.2 0.0 (0.10)
HbA1c (%)
B8 40 7.4 -0.9 (0.07) 40 7.3 0.0 (0.08)
[8 to B9 17 8.3 -1.1 (0.14) 14 8.5 0.0 (0.10)
[9 11 9.5 -1.6 (0.26) 16 9.4 -0.3 (0.17)
FPG (mmol/L)
\8.9 41 7.6 -1.0 (0.08) 34 7.3 -0.1 (0.06)
C8.9 27 8.6 -1.2 (0.14) 36 8.7 -0.1 (0.11)
BL baseline, BMI body mass index, FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, SE standard error
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relative to glucose levels, in turn decreasing the
endogenous glucose production overnight [21].
Overall, vildagliptin added to metformin was
safe with no new safety findings observed in
Japanese patients with T2DM. The observed
safety profile was similar with previously reported
52-week safety study of vildagliptin add-on to
metformin in Japanese patients with T2DM [22],
long-term study of vildagliptin add-on to
metformin in a predominantly Caucasian
population [23], and safety pooled analysis of
vildagliptin studies of C12 to C104 weeks
duration [24]. Four patients in the vildagliptin
group and one patient in the placebo group
reported clinically asymptomatic mild elevations
of amylase and/or lipase; however, none of these
cases were considered as an AE of acute pancreatitis
by the investigators. Similar to the previously
reported studies [25], treatment with vildagliptin
as add-on to metformin confirmed its weight
neutrality in Japanese patients.
There were no incidences of hypoglycemia
reported in the study. Absence of hypoglycemic
events in the vildagliptin group, in spite of lower
mean baseline FPG and HbA1c levels than the
Table 5 Number (%) of patients reporting common










Any preferred term 30 (44.1) 29 (41.4)
Nasopharyngitis 5 (7.4) 4 (5.7)
Amylase increased 4 (5.9) 1 (1.4)
Dental caries 2 (2.9) 0 (0.0)
Gastritis erosive 2 (2.9) 0 (0.0)
Tinea infection 2 (2.9) 0 (0.0)
Lipase increased 2 (2.9) 1 (1.4)
Hypoesthesia 2 (2.9) 0 (0.0)
Anemia 0 (0.0) 3 (4.3)
Diarrhea 0 (0.0) 2 (2.9)








0 (0.0) 2 (2.9)
Back pain 0 (0.0) 2 (2.9)
Headache 0 (0.0) 2 (2.9)
Tension headache 0 (0.0) 2 (2.9)
Fig. 4 a Fasting plasma glucose (FPG) by treatment and
visit (full analysis set). b Adjusted mean change in FPG
from baseline to endpoint (full analysis set). BL baseline,
EP endpoint, SE standard error. *P\0.001
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global study [11], confirms the glucose-dependent
action of vildagliptin. This is consistent with the
results from a previously reported large pooled
analysis of global safety data, which showed that
vildagliptin, as monotherapy or in combination
with metformin, thiazolidinedione, or
sulfonylurea, is associated with fewer
hypoglycemic events compared with
comparators [24].
The notable benefit observed in improving
HbA1c levels confirms the complementary
mechanism of action of vildagliptin and
metformin in Japanese patients with T2DM.
Metformin increases the plasma concentration of
incretin hormones and enhances the effects of
DPP-4 inhibition on the increase of intact GLP-1,
which might explain the improved efficacy of
vildagliptin in combination with metformin [26].
In conclusion, vildagliptin 50 mg bid as add-
on to metformin is effective in reducing HbA1c
and FPG levels without any tolerability issues
and hypoglycemia in Japanese patients with
T2DM inadequately controlled on metformin
monotherapy.
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